| Bioconda: sustainable and comprehensive software distribution for the life sciences B Grüning, R Dale, A Sjödin, BA Chapman, J Rowe, CH Tomkins-Tinch, ... Nature Methods 15, 475–476, 2018 | 892 | 2018 |
| Mutational profile of metastatic breast cancers: a retrospective analysis C Lefebvre, T Bachelot, T Filleron, M Pedrero, M Campone, JC Soria, ... PLoS medicine 13 (12), e1002201, 2016 | 377 | 2016 |
| Integrating deep learning CT-scan model, biological and clinical variables to predict severity of COVID-19 patients N Lassau, S Ammari, E Chouzenoux, H Gortais, P Herent, M Devilder, ... Nature communications 12 (1), 1-11, 2021 | 168 | 2021 |
| Frequent homologous recombination deficiency in high-grade endometrial carcinomas MM De Jonge, A Auguste, LM van Wijk, PC Schouten, M Meijers, ... Clinical Cancer Research 25 (3), 1087-1097, 2019 | 154 | 2019 |
| Familial predisposition to TP53/complex karyotype MDS and leukemia in DNA repair-deficient xeroderma pigmentosum A Sarasin, S Quentin, N Droin, M Sahbatou, V Saada, N Auger, Y Boursin, ... Blood, The Journal of the American Society of Hematology 133 (25), 2718-2724, 2019 | 42 | 2019 |
| Discovery of new fusion transcripts in a cohort of pediatric solid cancers at relapse and relevance for personalized medicine C Dupain, AC Harttrampf, Y Boursin, M Lebeurrier, W Rondof, ... Molecular Therapy 27 (1), 200-218, 2019 | 30 | 2019 |
| Added value of whole-exome and transcriptome sequencing for clinical molecular screenings of advanced cancer patients with solid tumors F Koeppel, A Bobard, C Lefebvre, M Pedrero, M Deloger, Y Boursin, ... The Cancer Journal 24 (4), 153-162, 2018 | 22 | 2018 |
| Improving the performance of somatic mutation identification by recovering circulating tumor DNA mutations Y Fu, C Jovelet, T Filleron, M Pedrero, N Motté, Y Boursin, Y Luo, ... Cancer research 76 (20), 5954-5961, 2016 | 19 | 2016 |
| Seeking the driver in tumours with apparent normal molecular profile on comparative genomic hybridization and targeted gene panel sequencing: what is the added value of whole … S Postel-Vinay, Y Boursin, C Massard, A Hollebecque, E Ileana, M Chiron, ... Annals of Oncology 27 (2), 344-352, 2016 | 13 | 2016 |
| Whole exome sequencing in molecular diagnostics of cancer decreases over time: evidence from a cost analysis in the French setting A Bayle, N Droin, B Besse, Z Zou, Y Boursin, S Rissel, E Solary, L Lacroix, ... The European Journal of Health Economics 22, 855-864, 2021 | 10 | 2021 |
| AI-based multi-modal integration of clinical characteristics, lab tests and chest CTs improves COVID-19 outcome prediction of hospitalized patients N Lassau, S Ammari, E Chouzenoux, H Gortais, P Herent, M Devilder, ... medRxiv, 2020.05. 14.20101972, 2020 | 9 | 2020 |
| Integrating deep learning CT-scan model, biological and clinical variables to predict severity of COVID-19 patients. Nat Commun. 2021; 12: 634 N Lassau, S Ammari, E Chouzenoux, H Gortais, P Herent, M Devilder, ... | 8 | |
| Integration of clinical characteristics, lab tests and a deep learning CT scan analysis to predict severity of hospitalized COVID-19 patients N Lassau, S Ammari, E Chouzenoux, H Gortais, P Herent, M Devilder, ... MedRxiv, 2020 | 3 | 2020 |
| ctDNA from ascites as an alternative to tumor sampling for HRD (homologous recombination deficiency) testing in ovarian cancer (OC). A Leary, R el Hazzaz, A Le Formal, E Lecerf, C Brizais, ... Journal of Clinical Oncology 38 (15_suppl), 6066-6066, 2020 | 1 | 2020 |
| 1591P Whole exome sequencing: Evolution of indications and cost to inform public health policy decision-making A Bayle, N Droin, B Besse, Z Zou, Y Boursin, S Rissel, E Solary, L Lacroix, ... Annals of Oncology 31, S963, 2020 | | 2020 |
| Genomic instability is associated with increased immune infiltration and PDL1 expression in epithelial ovarian cancer A Leary, C Genestie, Y Boursin, J Adam, A Leformal-Ensarguex, S Gouy, ... Annals of Oncology 28, v337-v338, 2017 | | 2017 |
| Abstract LB-353: Mutational profile of metastatic breast cancers using whole-exome sequencing: a retrospective analysis of 216 samples from SAFIR01/02/SHIVA/MOSCATO trials M Kamal, C Lefebvre, T Bachelot, T Filleron, M Pedrero, M Campone, ... Cancer Research 76 (14_Supplement), LB-353-LB-353, 2016 | | 2016 |
| Mutational profile of metastatic breast cancers using whole-exome sequencing: a retrospective analysis of 216 samples from SAFIR01/02/SHIVA/MOSCATO trials M Kamal, C Lefebvre, T Bachelot, T Filleron, M Pedrero, M Campone, ... CANCER RESEARCH 76, 2016 | | 2016 |
